WuXi Biologics (Cayman) (SZSC:2269) - Stock Price, News & Analysis

2269 Stock Overview

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.

About the company

2269 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 61.3% below our estimate of its fair value

Earnings are forecast to grow 13.74% per year

Trading at good value compared to peers and industry

Risk Analysis

Profit margins (20%) are lower than last year (29%)

Significant insider selling over the past 3 months

WuXi Biologics (Cayman) Inc. Competitors

WuXi XDC Cayman

SEHK:2268

HK$21.5b

Frontage Holdings

SEHK:1521

HK$1.8b

Sino Biopharmaceutical

SEHK:1177

HK$47.7b

China Resources Pharmaceutical Group

SEHK:3320

HK$36.8b

Price History & Performance

Summary of all time highs, changes and price drops for WuXi Biologics (Cayman)
Historical stock prices
Current Share Price	HK$11.60
52 Week High	HK$52.45
52 Week Low	HK$10.88
Beta	0.58
11 Month Change	-9.94%
3 Month Change	-11.04%
1 Year Change	-69.27%
33 Year Change	-91.85%
5 Year Change	n/a
Change since IPO	-84.92%

Recent updates

Shareholder Returns

	2269	HK Life Sciences	HK Market
7D	-1.2%	-0.5%	0.6%
1Y	-69.3%	-65.8%	2.4%

Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -65.8% over the past year.

Return vs Market: 2269 underperformed the Hong Kong Market which returned 2.4% over the past year.

Price Volatility

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	9.6%
Market Average Movement	7.2%
10% most volatile stocks in HK Market	15.3%
10% least volatile stocks in HK Market	3.7%

Stable Share Price: 2269's share price has been volatile over the past 3 months.

Volatility Over Time: 2269's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	12,740	Chris Chen	www.wuxibiologics.com

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.

WuXi Biologics (Cayman) Inc. Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 fundamental statistics
Market cap	HK$48.16b
Earnings (TTM)	HK$3.65b
Revenue (TTM)	HK$18.31b

13.2x

P/E Ratio

2.6x

P/S Ratio

Is 2269 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2269 income statement (TTM)
Revenue	CN¥17.03b
Cost of Revenue	CN¥10.21b
Gross Profit	CN¥6.83b
Other Expenses	CN¥3.43b
Earnings	CN¥3.40b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.82
Gross Margin	40.08%
Net Profit Margin	19.96%
Debt/Equity Ratio	4.9%

How did 2269 perform over the long term?

See historical performance and comparison

2269 Stock Overview

Rewards

Risk Analysis

WuXi Biologics (Cayman) Inc. Competitors

SEHK:2268

HK$21.5b

SEHK:1521

HK$1.8b

SEHK:1177

HK$47.7b

SEHK:3320

HK$36.8b

Price History & Performance

Recent News & Updates

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Recent updates

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week